Viagra Cannot Perform In Women: Pfizer Ends Female Sexual Arousal Disorder Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical studies "do not support a regulatory filing" in female sexual dysfunction because efficacy data were "inconclusive," the company says.
You may also be interested in...
BioSante LibiGel Study Design Changes Could Yield Better Results For Sexual Dysfunction
Two more Phase III studies for the hypoactive sexual desire disorder therapy is the firm’s best financial investment, CEO Simes says, because the revised design is expected to eliminate the greater-than-expected placebo response that derailed the previous studies.
BioSante LibiGel Study Design Changes Could Yield Better Results For Sexual Dysfunction
Two more Phase III studies for the hypoactive sexual desire disorder therapy is the firm’s best financial investment, CEO Simes says, because the revised design is expected to eliminate the greater-than-expected placebo response that derailed the previous studies.
King/Mylan Merger Will Provide Critical Mass To Develop Palatin's ED Agent
King will pay up to $250 mil. to in-license the Phase II agent PT-141 for female sexual dysfunction and erectile dysfunction. King says the melanocortin receptor agonist will provide better safety and efficacy compared to the currently marketed PDE-5 inhibitors.